Optimizing opioid treatment in cancer patients.

Optimising opioid treatment for patients with cancer involves careful assessment, patient-centred communication, dose titration, management of side effects, and regular review.

Start strong opioid treatment with either oral sustained-release or immediate-release morphine, according to patient preference, accompanied by immediate-release morphine for breakthrough pain rescue doses. Typical starting doses for patients without renal or hepatic impairment are 20–30 mg of oral morphine daily (e.g., 10–15 mg sustained-release twice daily) plus 5 mg immediate-release for breakthrough symptoms, adjusting until pain control is balanced with side effects. Frequent review, especially during titration, is crucial; if balance is not achieved, seek specialist advice. For patients with moderate to severe renal or hepatic impairment, specialist advice prior to opioid initiation is needed NICE CG140.

Oral sustained-release morphine is the first-line maintenance opioid, avoiding transdermal patches as routine first-line treatment for patients suitable for oral opioids. If oral opioids are unsuitable and analgesic needs are stable, consider transdermal patches, selecting the lowest acquisition cost formulation with specialist support. Where analgesic requirements are unstable or the oral route inappropriate, subcutaneous opioids may be considered, again guided by specialists NICE CG140.

For breakthrough pain in patients on oral maintenance morphine, oral immediate-release morphine is the first-line rescue medication; fast-acting fentanyl should not be offered first-line NICE CG140. Breakthrough pain management can also involve sublingual opioid formulations licensed for cancer breakthrough pain SmPC Fenhuma,SmPC Abstral,SmPC Fenhuma.

Constipation affects nearly all patients on strong opioids; prescribe regular, effective-dose laxatives from the start, emphasising adherence and titrating laxatives with opioid dose increases. Manage constipation proactively before considering opioid switching NICE CG140,NICE CKS.

Nausea and drowsiness are common side effects at opioid initiation or dose increases but often transient. Persistent nausea should be managed with anti-emetics before changing opioids. Persistent moderate-to-severe central nervous system side effects may require dose reduction or opioid rotation, with specialist input if uncontrolled NICE CG140.

Use validated pain assessment tools and incorporate patients’ preferences, quality-of-life impacts, and the type of pain (somatic, visceral, neuropathic) in developing personalised pain management plans. Regularly review analgesic efficacy and tolerability, adjusting doses or treatments as necessary, and consider non-opioid adjuvants for neuropathic or spasm-related pain. Seek specialist palliative care advice when pain is difficult to control, adverse effects persist, or unusual opioid regimens/routes are required NICE CKS,NICE NG234.

Patients should be actively involved in discussions addressing concerns such as addiction, tolerance, side effects, and the psychosocial implications of opioid treatment, ensuring informed decisions and adherence to therapy NICE CG140,NICE NG234.